NanoVibronix, Inc. announced that it has entered into a non-binding letter of intent (the LOI) with APOGEPHA Arzneimittel GmbH in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix?s premiere UroShield product in Germany and other European markets. Under the terms of the LOI, APOGEPHA will commence a comprehensive market evaluation on how UroShield fits into the pathway of care for patients with long term catheters. The goal of the LOI, and subsequent findings, will be for both NanoVibronix and APOGEPHA to better understand the feasibility of a distribution deal between both companies.